Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	The contents of the displayed table are downloaded as a file named "table.csv".
	A text longer than 100 characters is fully displayed or collapsed.

DR info

Clinical trials : 4 / Drugs : 9 - (DrugBank : 2) / Drug target gene : 1 - Drug target pathways : 4

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countires)

PLA-PRU-PLA-PRU
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom;
PLA-PRU-PRU-PLA
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom;
PRU-PLA-PLA-PRU
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom;
PRU-PLA-PRU-PLA
   Movetis
      2008   Phase 2   NCT00793247   United Kingdom;
Rifaximin
   Ohkubo Hidenori
      2019   Phase 2   JPRN-jRCT2031190137   Japan;
Rifaximin oral tablet
   Yokohama City University
      2019   Phase 2   NCT04118699   Japan;
TD-5108 hydrochloride
   ALFASIGMA S.P.A.
      2021   Phase 2   EUCTR2021-000854-24-IT   Belgium;Italy;Spain;
THRX-199687 hydrochloride
   ALFASIGMA S.P.A.
      2021   Phase 2   EUCTR2021-000854-24-IT   Belgium;Italy;Spain;
Velusetrag
   ALFASIGMA S.P.A.
      2021   Phase 2   EUCTR2021-000854-24-IT   Belgium;Italy;Spain;